Is COO a Buy or a Sell? The Bull and Bear Case (2026)

Last updated July 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for The Cooper Companies (COO) rests on Myopia management and premium lens mix: CooperVision's growth comes less from unit volume than from moving wearers up the price ladder into daily silicone hydrogel, torics and multifocals. The bear case rests on asia-Pacific is the immediate problem: consumer weakness in Japan and China pushed CooperVision revenue in the region down ~6% and forced a trim to full-year revenue guidance in June 2026, with roughly ~$22M of tariff costs and second-half currency headwinds layered on top. Analysts covering it publish targets from $66.00 to $92.00 against a $69.73 price, so even the professionals disagree by 32% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

The Cooper Companies, headquartered in San Ramon, California and employing roughly ~15,000 people, has run on the same two-segment structure for years. CooperVision, about two thirds of revenue at ~$723.5M in the April 2026 quarter, makes soft contact lenses: daily disposables in silicone hydrogel, torics for astigmatism, multifocals for presbyopia, and MiSight 1 day, the only daily disposable lens with FDA approval to slow the progression of myopia in children. CooperSurgical, the other third at ~$358.0M, splits into fertility (IVF consumables, embryo culture media, cryostorage and genetic testing sold to fertility clinics) and an office and surgical line of devices sold into OB/GYN practices. The fiscal year ends October 31, so results labelled fiscal 2026 largely cover calendar 2026. The investment picture in September 2026 is unusually two-sided. Trailing revenue of ~$4.23B grew ~6%, gross margin held at ~68% and non-GAAP operating margin improved to ~27%, yet the shares sit near ~$70 against a 52-week range of roughly ~$59 to ~$90. Three things pulled them down: a June guidance trim driven by consumer weakness in Japan and China, a ~$271.6M net pre-tax charge to settle claims from the December 2023 embryo culture media recall at CooperSurgical, and the uncertainty of a formal strategic review that began in December 2025 under pressure from activists JANA Partners and Browning West. That review has already produced a new board chair and advanced discussions to sell CooperSurgical outright, with proceeds earmarked for buybacks and paying down the ~$2.46B of debt on the balance sheet.

The bull case: what would have to be true for $92.00

The most optimistic published target on COO is $92.00, +31.9% from the $69.73 price as of September 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Myopia management and premium lens mix

CooperVision's growth comes less from unit volume than from moving wearers up the price ladder into daily silicone hydrogel, torics and multifocals. MiSight 1 day sits at the top of that ladder, and Cooper has been extending it into Japan, Australia and New Zealand, markets where childhood myopia rates are among the highest in the world (as many as ~77% of Japanese elementary school children are estimated to be myopic). Pediatric myopia control is a category Cooper largely created, and it carries better pricing and stickier patient relationships than commodity spheres.

2. The CooperSurgical sale and a simpler company

The strategic review announced on December 4, 2025 put the whole portfolio on the table, including divestitures, joint ventures and combinations. Management has since confirmed advanced discussions with multiple parties holding significant indications of interest in CooperSurgical, with sell-side estimates of the unit clustering near ~$4.1B, and has said net proceeds would go mainly to share repurchases and debt reduction. A completed sale would leave a pure-play contact lens company with higher margins, lower leverage and a far simpler story to underwrite.

3. Fertility volumes inside CooperSurgical

Fertility is the fastest-growing line Cooper owns, at ~$143.8M in the April quarter and up ~13% year over year, against ~4% growth in the office and surgical products sold to OB/GYN practices. Later family formation, wider employer IVF coverage and clinic consolidation all push volumes in the same direction, and Cooper supplies the consumables, culture media, cryostorage and genetic testing that clinics buy repeatedly. Whether shareholders keep that exposure past this year depends entirely on the divestiture.

4. Cash generation, buybacks and deleveraging

Gross margin of ~68% and non-GAAP operating margin of ~27% mean the underlying business still converts revenue into cash in a soft demand year. Free cash flow of ~$96.4M in the April quarter was held back by heavy manufacturing capex of ~$86.4M as lens capacity expands, a real call on cash but a finite one. Cooper has retired shares steadily over the past decade and has flagged buybacks as the primary use of any sale proceeds, alongside cutting the ~$2.46B debt load.

The bear case: what would have to be true for $66.00

The most pessimistic published target is $66.00, -5.3% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks The Cooper Companies is worth if the risks below bite instead of the drivers above.

Asia-Pacific is the immediate problem: consumer weakness in Japan and China pushed CooperVision revenue in the region down ~6% and forced a trim to full-year revenue guidance in June 2026, with roughly ~$22M of tariff costs and second-half currency headwinds layered on top. The December 2023 recall of three lots of LifeGlobal embryo culture media at CooperSurgical produced more than 140 lawsuits and over 1,500 claimants, and the ~$271.6M net charge booked to resolve substantially all of those claims turned the April quarter into a GAAP loss, with some residual exposure remaining. The breakup carries risk in both directions, since a sale might not close, might price below the ~$4.1B figure being discussed, or might remove the faster-growing fertility franchise from shareholders. CooperVision also competes against Johnson and Johnson, Alcon and Bausch and Lomb, all of which have deeper balance sheets and can price aggressively when the market slows. Activist involvement and a board leadership transition add the ordinary uncertainty of a company being reshaped while it operates.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding COO already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on COO

14 analysts cover COO, with an average target of $81.50 (+16.9% against $69.73) and a split of 10 buy, 6 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the COO forecast and price target page.

How is COO valued? (as of September 2026)

Price

$69.73

Market cap

$13.60B

P/E (TTM)

58.60

Forward P/E

13.96

Price / book

1.65

Beta

0.82

52-week range

$58.89 to $89.83

Snapshot for COO as of September 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): ~$4.23B, up ~6%
Fiscal 2026 revenue guidance: ~$4.285B to ~$4.321B (~3.5% to ~4.5% organic)
Fiscal 2026 non-GAAP EPS guidance: ~$4.58 to ~$4.66
Forward P/E on that guidance: ~15x at ~$70 per share
GAAP P/E (TTM): ~59x on GAAP EPS of ~$1.18
Total debt (April 30, 2026): ~$2.46B

GAAP and non-GAAP diverge sharply here, and the gap explains most of the odd-looking headline multiple. Trailing GAAP EPS of ~$1.18 absorbs the ~$271.6M litigation charge plus purchase-accounting amortization from years of CooperSurgical acquisitions, while management guides on non-GAAP EPS of ~$4.58 to ~$4.66, which puts the shares near ~15x, below the multiple Cooper carried through most of the last decade. Fiscal third-quarter results are scheduled for September 9, 2026, and the fiscal year closes October 31.

How do you decide if COO is a buy?

Rather than asking whether COO is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the bull case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold COO indirectly through an index or sector ETF before adding more.

What would change your mind on COO

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

Bull case breaks if: Myopia management and premium lens mix stalls in the reported numbers rather than in the narrative around them.
Bear case breaks if: asia-Pacific is the immediate problem: consumer weakness in Japan and China pushed CooperVision revenue in the region down ~6% and forced a trim to full-year revenue guidance in June 2026, with roughly ~$22M of tariff costs and second-half currency headwinds layered on top fails to materialise over several reporting periods while the drivers keep compounding.
Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the COO stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about COO against your real portfolio and see your actual exposure before deciding.

Investing in The Cooper Companies with AI

Connect the broker you already use and ask Walnut's AI how COO fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

Does COO fit me?

FAQ

Is COO a good stock to buy right now?

That depends on which case you find more convincing, and both are on this page. The bull case rests on Myopia management and premium lens mix, with revenue (ttm) at ~$4.23B, up ~6%. The bear case rests on asia-Pacific is the immediate problem: consumer weakness in Japan and China pushed CooperVision revenue in the region down ~6% and forced a trim to full-year revenue guidance in June 2026, with roughly ~$22M of tariff costs and second-half currency headwinds layered on top. Analysts covering it are spread from $66.00 to $92.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Should I sell COO?

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Asia-Pacific is the immediate problem: consumer weakness in Japan and China pushed CooperVision revenue in the region down ~6% and forced a trim to full-year revenue guidance in June 2026, with roughly ~$22M of tariff costs and second-half currency headwinds layered on top. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $66.00, -5.3% from the $69.73 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

What is the bull case for COO?

Myopia management and premium lens mix. CooperVision's growth comes less from unit volume than from moving wearers up the price ladder into daily silicone hydrogel, torics and multifocals. The most optimistic analyst target on COO is $92.00, +31.9% from the $69.73 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for COO?

What does The Cooper Companies do?

The Cooper Companies runs two medical device businesses: CooperVision in soft contact lenses and myopia management, and CooperSurgical in fertility and women's health.

What would have to change for COO to stop being worth holding?

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Myopia management and premium lens mix) stalling in the reported numbers rather than in the narrative, the risk above (asia-Pacific is the immediate problem: consumer weakness in Japan and China pushed CooperVision revenue in the region down ~6% and forced a trim to full-year revenue guidance in June 2026, with roughly ~$22M of tariff costs and second-half currency headwinds layered on top) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does The Cooper Companies actually do?

It runs two medical device businesses. CooperVision, roughly two thirds of revenue, makes soft contact lenses including dailies, torics, multifocals and the MiSight myopia control lens for children. CooperSurgical, the other third, sells fertility products such as IVF consumables and culture media plus devices used in OB/GYN offices and surgery.

Has COO done a stock split? The price looks low for a company this size.

Yes. Cooper completed a 4-for-1 stock split effective February 16, 2024, with split-adjusted trading beginning February 20, 2024. The ~$70 quote is post-split, equivalent to roughly ~$280 on the old share count. Any per-share figure taken from before February 2024 needs dividing by four before comparing.

How big is each segment?

In the quarter ended April 30, 2026, CooperVision produced ~$723.5M of revenue (up ~4% organically) and CooperSurgical ~$358.0M (up ~6% organically). Within CooperSurgical, fertility was ~$143.8M and up ~13%, while office and surgical products were ~$214.2M and up ~4%.

Walnut is informational, not investment advice, and gives no verdict on COO. Analyst targets referenced here come from a September 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.